Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Malcolm Risk"'
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-7 (2024)
Abstract We compared the risks and benefits of COVID-19 vaccines using a causal pathway analysis to weigh up possible risk factors of thromboembolic events post-vaccination. The self-controlled case series (SCCS) method examined the association betwe
Externí odkaz:
https://doaj.org/article/2af3b1c257a64a4eaa7cff24c9cc1cb6
Autor:
Malcolm, Risk, Salim S, Hayek, Elena, Schiopu, Liyang, Yuan, Chen, Shen, Xu, Shi, Gary, Freed, Lili, Zhao
Publikováno v:
The Lancet Rheumatology. 4:e775-e784
There is a scarcity of research regarding the effectiveness of the mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in patients taking immunosuppressant medications, and no data are published to date pertaining to their effectiven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5271dc2a976dd1c6b33aff5497022246
https://doi.org/10.1016/s2665-9913(22)00216-8
https://doi.org/10.1016/s2665-9913(22)00216-8
Publikováno v:
The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 72(1)
The BNT162b2 (Pfizer-BioNTech) is approved for adolescents aged 12-17 years. We estimated BNT162b2 vaccine effectiveness (VE) and a booster dose effectiveness in adolescents aged 12-17 years and the impact of opening schools and the Omicron variant o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b2beb4c6876de42d1f8e57ae559fd19
https://pubmed.ncbi.nlm.nih.gov/36216679
https://pubmed.ncbi.nlm.nih.gov/36216679
Autor:
Chen Shen, Malcolm Risk, Elena Schiopu, Salim S Hayek, Tiankai Xie, Lynn Holevinski, Cem Akin, Gary Freed, Lili Zhao
Publikováno v:
Ann Rheum Dis
ObjectivesWe intended to assess the effectiveness of all three US Food and Drug Administration approved COVID-19 vaccines at preventing SARS-CoV-2 infection and COVID-19 hospitalisation in a large cohort of individuals on immunosuppressants for a div
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::471b8b4d97e64bf6d4d495b1ebf87c94
https://europepmc.org/articles/PMC9422955/
https://europepmc.org/articles/PMC9422955/
Autor:
Malcolm Risk, Chen Shen, Salim S Hayek, Lynn Holevinski, Elena Schiopu, Gary Freed, Cem Akin, Lili Zhao
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 75(1)
Background There is a lack of data regarding how the Delta variant of coronavirus disease 2019 (COVID-19) has impacted the effectiveness of the BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Johnson & Johnson–Janssen) vaccines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ef076a76d5fd6b49c53a36368c12c5
https://pubmed.ncbi.nlm.nih.gov/35137006
https://pubmed.ncbi.nlm.nih.gov/35137006